Patents Examined by Brian E McDowell
  • Patent number: 11999722
    Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: June 4, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Andrew Coates, Timothy Barrett Durham, Richard Duane Johnston, Steven Marc Massey, Patrick Gianpietro Spinazze, Douglas Richard Stack, James Lee Toth
  • Patent number: 11999720
    Abstract: This invention relates to pyrazolylacylpyrazoline compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat neurological disorders.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: June 4, 2024
    Assignees: THE TRUSTEES OF INDIANA UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Samy Meroueh, Fletcher A. White, Alexander G. Obukhov
  • Patent number: 11993618
    Abstract: The invention relates to complexing agents of formula (I): wherein Chrom1, Chrom2 and Chrom3 are as defined in the description. The invention also relates to lanthanide complexes obtained from these complexing agents.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: May 28, 2024
    Assignee: CISBIO BIOASSAYS
    Inventors: Laurent Lamarque, Jurriaan Zwier, Emmanuel Bourrier
  • Patent number: 11986480
    Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: May 21, 2024
    Assignee: TOHOKU UNIVERSITY
    Inventors: Hirokazu Arimoto, Kaori Itto, Daiki Takahashi, Nobuo Cho, Hiroshi Nara, Kenichiro Shimokawa, Taiichi Ohra, Shigekazu Sasaki, Naoki Ishii
  • Patent number: 11987578
    Abstract: A 7-(4-((5-(2-chlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent.
    Type: Grant
    Filed: February 6, 2024
    Date of Patent: May 21, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11987587
    Abstract: The present invention provides novel chiral bisamino-ether compounds, and method of preparation and use thereof. The chiral bisamino-ether compounds have the structure of formula (I). The method of preparation includes: using chiral aminomethanol compounds as starting materials to react with halogenated aryl compounds in the presence of a base to give a variety of chiral bisamino-ether compounds. The novel chiral bisamino-ether compounds can be used for asymmetric fluorocyclization of unsaturated heterocyclic compounds with excellent enantioselectivity and great potentials for industrial applications.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: May 21, 2024
    Inventors: Xiaojian Jiang, Ying Yeung Yeung
  • Patent number: 11987572
    Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1, R2, R3, A, B, D, E, F and G have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as bromodomain inhibitors.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: May 21, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Joseph J. Topczewski, William C. K. Pomerantz, Angela S. Carlson, Huarui Cui, Anand Divakaran
  • Patent number: 11987574
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: May 21, 2024
    Assignee: XinThera, Inc.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman
  • Patent number: 11981663
    Abstract: The invention provides novel benzamides of pyrazolyl-amino-pyrimidinyl derivatives of Formula (I) as selective and potent JAK inhibitors for treating various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Grant
    Filed: September 10, 2023
    Date of Patent: May 14, 2024
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Xiaodong Li
  • Patent number: 11981675
    Abstract: Novel pyrrolo[3,2-c]quinoline-2,3-dione compounds having the formula I as described below, with all substituents as defined in the instant specification, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c]quinoline-2,3-dione compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 12, 2023
    Date of Patent: May 14, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11970496
    Abstract: Novel pyrrolo[3,2-c]quinoline compounds, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c]quinoline compounds, identified as CK2 inhibitors, have the following formula I with the substituents as defined in the instant specification, and are useful as anticancer and/or antitumor agents, and as agents for treating other kinase associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 7, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Michelyne Haroun, Christophe Tratrat
  • Patent number: 11970472
    Abstract: A 5-((2-isopropyl-5-methylphenoxy)methyl)-3-(naphthalen-1-yl)-1,2,4-oxadiazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11970487
    Abstract: A 7-(4-((5-(benzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent, and having the formula:
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11958851
    Abstract: Novel pyrrolo[3,2-c]quinoline compounds, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c]quinoline compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 7, 2023
    Date of Patent: April 16, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Michelyne Haroun, Christophe Tratrat
  • Patent number: 11952386
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • Patent number: 11951170
    Abstract: The present disclosure provides a compound comprising a modified tetracycline derivative, covalently coupled through a linker to a low-hydrophobicity bioactive molecule useful for treating neurodegenerative diseases, wherein the modified tetracycline derivative is optionally defined by the following formula:
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: April 9, 2024
    Assignees: Skybio LLC, Consejo Nacional de Investigaciones Cientificas y Ténicas (Conicet), Universidad Nacional de Tucumán, Universidad de Buenos Aires, Sistema Provincial De Salud De Tucumán
    Inventors: Oscar José Varela, Rosana Nieves Chehín, Cesar Luis Ávila, Sergio Benjamin Socías, Diego Ploper, Esteban Vera Pingitore, Analía Silvina Chaves, Martin Luong, Verónica Elena Manzano, Rodrigo Hernán Tomas Grau, Maria Florencia González Lizárraga, Adriana Andrea Kolender, Agustín Osvaldo Pernicone
  • Patent number: 11952369
    Abstract: The present disclosure provides metabolites of belumosudil and uses of the metabolites in of treating patients with ROCK2-mediated diseases including cGVHD.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: April 9, 2024
    Assignee: Kadmon Corporation, LLC
    Inventors: Olivier Schueller, Jeegar P. Patel
  • Patent number: 11945818
    Abstract: Novel pyrrolo[3,2-c]quinoline compounds of the formula I, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c]quinoline compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: September 6, 2023
    Date of Patent: April 2, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Michelyne Haroun, Christophe Tratrat
  • Patent number: 11939329
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: March 26, 2024
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • Patent number: 11932649
    Abstract: Compounds for treating cancer and, particularly, to compounds that are 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione analogues and their use as anticancer agents. The compounds have the structure: wherein: R1 is selected from the group consisting of hydrogen, hydroxy, and benzyloxy; R2 is selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkoxy, and benzyloxy; R3 is selected from the group consisting of hydrogen and a C1-C6 straight or branched chain alkyl; and R4 is selected from the group consisting of hydrogen and a C1-C6 straight or branched chain alkyl.
    Type: Grant
    Filed: August 17, 2023
    Date of Patent: March 19, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Pran Kishore Deb, Vinuta Kamat, Rangappa Santosh, Boja Poojary, Manohar S. Kugaji, Vijay M. Kumbar, Mohamed A. Morsy, Bandar Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha